EUVIMEDEUVIMED entdecken
Kohortenstudie

Prognostic Evaluation of Conversion Therapy following Hepatic Arterial Infusion Chemotherapy or Immunotherapy in Patients with Advanced or Transarterial Chemoembolization Unsuitable Intermediate-Stage Hepatocellular Carcinoma: A Retrospective Cohort Study

Li-Fu Kuo, Wen-Chun Liu, Ming-Feng Li, Fu-Huan Huang, Chu-Kuang Chou, Tsung-Hsien Chen, Yi-Tseng Tsai, Ping-I Hsu, Chao-Jen Li, I-Ting Wu, Kun-Feng Tsai

Oncology · 2024

DOI: 10.1159/000542291 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Oncology, 2024. Verfasst von Li-Fu Kuo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology and Hepatology Section, Department of Internal Medicine, An Nan Hospital, China Medical University, Tainan, Taiwan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Immunotherapy, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Patients with advanced-stage or intermediate-stage hepatocellular carcinoma (HCC) unsuitable for transarterial chemoembolization (TACE) had poor prognoses. Recent advancements in hepatic arterial infusion chemotherapy (HAIC) and immune checkpoint inhibitors (ICIs) have demonstrated higher tumor response rates, which improved overall survival (OS). HAIC achieves an OS rate of approximately 14.5–15.3 months with a 39.1–42.5% tumor response rate. In comparison, ICIs have a 12–14 month OS rate with a 26–33% tumor response rate. Given these promising responses, this study evaluates the efficacy of conversion therapy with curative intent following HAIC or ICIs, focusing on survival outcomes.

Methods

We retrospectively analyzed 80 patients with advanced or TACE-unsuitable intermediate HCC. Patients completed two HAIC or four ICI cycles, followed by Response Evaluation Criteria in Solid Tumors (RECIST) criteria imaging. Based on demographics, cirrhosis status, Barcelona Clinic Liver Cancer classification (BCLC) stage, treatment responses, and treatment modality, survival impacts were analyzed. OS was compared between HAIC and immunotherapy groups. The effect of conversion therapy with curative intent on survival outcomes was analyzed using a Cox regression model.

Results

Among the 80 patients, 26 achieved positive response (CR/PR) with HAIC or ICIs, and 9 of them subsequently underwent conversion therapy with curative intent. Key prognostic factors included Child-Pugh stage B versus A (HR = 2.21, p = 0.041), BCLC stage C versus B (HR = 4.38, p = 0.011), and elevated alpha-fetoprotein levels (HR = 5.02, p < 0.001). Positive responders saw substantial survival benefits (HR = 0.26, p = 0.001). Patients undergoing conversion therapy exhibited significantly enhanced survival. Median OS was 13.58 months with standard therapy, while the curative intent surgery group did not reach the median OS (p = 0.002). For CR/PR patients, 48-month survival was 75.0% for the curative surgery group versus 38.0% for standard treatment.

Conclusion

Conversion therapy with curative intent following HAIC or ICIs might enhance survival in patients with advanced or TACE-unsuitable intermediate-stage HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsImmunotherapyImmune Checkpoint InhibitorsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleRetrospective StudiesMiddle AgedInfusions, Intra-ArterialAgedChemoembolization, TherapeuticPrognosisNeoplasm StagingAdultTreatment OutcomeHepatic Artery

Stichwörter der Autor:innen

Advanced hepatocellular carcinomaCurative intent surgeryHepatic arterial infusion chemotherapyImmune checkpoint inhibitorsSurvival rate

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Gastroenterology and Hepatology Section, Department of Internal Medicine, An Nan Hospital, China Medical University, Tainan, Taiwan.
  • Department of Nursing, National Tainan Junior College of Nursing, Tainan, Taiwan.
  • Department of Radiology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
  • Department of Medical Imaging and Radiology, Shu-Zen Junior College of Medicine and Management, Kaohsiung, Taiwan.
  • Division of Pediatric Surgery, Department of Surgery, Taipei Medical University Hospital, Taipei, Taiwan.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi, Taiwan.

Zitieren

APA

Kuo, L. F., Liu, W. C., Li, M. F., Huang, F. H., Chou, C. K., Chen, T. H., Tsai, Y. T., Hsu, P. I., Li, C. J., Wu, I. T., & Tsai, K. F. (2024). Prognostic Evaluation of Conversion Therapy following Hepatic Arterial Infusion Chemotherapy or Immunotherapy in Patients with Advanced or Transarterial Chemoembolization Unsuitable Intermediate-Stage Hepatocellular Carcinoma: A Retrospective Cohort Study. Oncology. https://doi.org/10.1159/000542291

Vancouver

Kuo LF, Liu WC, Li MF, Huang FH, Chou CK, Chen TH, et al. Prognostic Evaluation of Conversion Therapy following Hepatic Arterial Infusion Chemotherapy or Immunotherapy in Patients with Advanced or Transarterial Chemoembolization Unsuitable Intermediate-Stage Hepatocellular Carcinoma: A Retrospective Cohort Study. Oncology. 2024. doi:10.1159/000542291

BibTeX
@article{Kuo2024,
  author = {Kuo, Li-Fu and Liu, Wen-Chun and Li, Ming-Feng and Huang, Fu-Huan and Chou, Chu-Kuang and Chen, Tsung-Hsien and Tsai, Yi-Tseng and Hsu, Ping-I and Li, Chao-Jen and Wu, I-Ting and Tsai, Kun-Feng},
  title = {Prognostic Evaluation of Conversion Therapy following Hepatic Arterial Infusion Chemotherapy or Immunotherapy in Patients with Advanced or Transarterial Chemoembolization Unsuitable Intermediate-Stage Hepatocellular Carcinoma: A Retrospective Cohort Study},
  journal = {Oncology},
  year = {2024},
  doi = {10.1159/000542291}
}
Kostenlos starten →